Skip to main content

Table 3 Model evaluation by LSSA and RNA-sequencing analysis (Chemoth stands for chemotherapy)

From: p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification

Source scenario in patients Target scenario in patients LSSA simulation Total number of genes Number of correct predictions p-value of correct predictions Number of small error predictions Number of large error predictions
TP53 wild type treated with chemoth TP53 mutant treated with chemoth TP53 null with DNA damage ON vs TP53 wt with DNA damage ON 200 104 (52%) 2.03 × 10−8 90 (45%) 6 (3%)
TP53 wild type not treated with chemoth TP53 mutant not treated with chemoth TP53 null with DNA damage OFF vs TP53 wt with DNA damage OFF 200 109 (54.5%) 3.77 × 10−10 86 (43%) 5 (2.5%)
TP53 mutant not treated with chemoth TP53 mutant treated with chemoth TP53 null with DNA damage ON vs TP53 null with DNA damage OFF 200 150 (75%) 1.92 × 10−33 46 (23%) 4 (2%)
TP53 wild type not treated with chemoth TP53 wild type treated with chemoth TP53 wt with DNA damage ON vs TP53 wt with DNA damage OFF 200 168 (84%) 1.921.92 × 10−49 31 (15.5%) 1 (0.5%)